Gemcitabine-Based Adjuvant Chemotherapy Improves Survival After Aggressive Surgery for Hilar Cholangiocarcinoma

摘要: The prognosis of hilar cholangiocarcinoma is dismal although aggressive surgery including major hepatectomy has been performed. aim this study was to clarify useful prognostic factors and the usefulness gemcitabine-based adjuvant chemotherapy for patients with who had undergone surgical resection. Medical records 42 underwent resection were reviewed retrospectively. Univariate multivariate models used analyze effect various clinicopathological on long-term survival. Overall 1-, 3-, 5-year survival rates 81%, 42%, 30%, respectively (median time, 21.5 months). analysis revealed that chemotherapy, tumor differentiation, lymph node metastasis, margin status associated significantly (P < 0.05). Furthermore, use a Cox proportional hazards regression model indicated only significant independent predictor favorable (P = 0.035). toxicity mild. Five-year actuarial did or not receive 57% 23%, (P = 0.026). Postoperative may be promising strategy improve after cholangiocarcinoma. A prospective randomized should done confirm results study.